NCT01618214 - Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

344

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.

Trial Locations (22)

100029

Novo Nordisk Investigational Site, Beijing

100088

Novo Nordisk Investigational Site, Beijing

100700

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

130041

Novo Nordisk Investigational Site, Changchun

136000

Novo Nordisk Investigational Site, Siping

200072

Novo Nordisk Investigational Site, Shanghai

210011

Novo Nordisk Investigational Site, Nanjing

225001

Novo Nordisk Investigational Site, Yangzhou

230001

Novo Nordisk Investigational Site, Hefei

230022

Novo Nordisk Investigational Site, Hefei

250013

Novo Nordisk Investigational Site, Jinan

310003

Novo Nordisk Investigational Site, Hangzhou

330006

Novo Nordisk Investigational Site, Nanchang

400010

Novo Nordisk Investigational Site, Chongqing

404000

Novo Nordisk Investigational Site, Chongqing

430034

Novo Nordisk Investigational Site, Wuhan

510080

Novo Nordisk Investigational Site, Guangzhou

710032

Novo Nordisk Investigational Site, Xi'an

050051

Novo Nordisk Investigational Site, Shijiazhuang

050082

Novo Nordisk Investigational Site, Shijiazhuang

028007

Novo Nordisk Investigational Site, Tongliao